Research, PHARMACY MARKET

Best practices in viral vector analytical characterization

December 13, 2022

Best practices in viral
Viral vectors are a critical part of the advanced therapies
supply chain as they are used to introduce the gene of
interest, whether that’s into a cell intended for therapeutic
gene transfer or for direct viral-mediated gene transfer into
the patient.

Spotlight

National Institute of Molecular Genetics

The Istituto Nazionale di Genetica Molecolare (INGM) is a no-profit research foundation aimed at the discovery and initial development of new therapies and new diagnostics in the fields of tumors and autoimmune diseases. INGM comes to life to be a “translational” medical Research Institute that creates scientific knowledge capable of generating value on the basis of the intellectual property that ensues from its research activities. To achieve these objectives, INGM will develop scientific research strongly connected with clinics, drawing benefit from being located inside one of the most important European hospitals, the IRCCS Ospedale Maggiore of Milan. Research activities are coordinated by a Chief Scientific Officier with scientific and managerial expertise who is supported by a Scientific Advisory Board composed by researchers having a high international profile.

OTHER WHITEPAPERS
news image

Ultimate Pharma Messaging Guidebook

whitePaper | March 10, 2023

This pharma messaging guidebook features 20 proven cognitive science techniques that can be used to optimize pharmaceutical claims and messages.

Read More
news image

Regenerative Medicine

whitePaper | September 16, 2022

T wice a year, we survey the cell and gene therapy landscape and ARM’s initiatives to advance the sector and provide an update to our members.

Read More
news image

Optimizing the Path from Pre-Clinical to Clinical Development

whitePaper | December 22, 2022

According to research, post-pandemic R&D growth is healthy in the pharma industry with the number of drugs in the R&D pipeline now exceeding 20,000 in 2022—which represents an expansion rate of 8.22% from 2021 (1).

Read More
news image

The Annual Clinical Trials Round-up 2021

whitePaper | October 13, 2022

In our previous edition of the Clinical Trials Roundup1, we explored the acute disruptions that the COVID-19 pandemic brought to the clinical trials landscape in 2020.

Read More
news image

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO) to support the conversion.

Read More
news image

Advancing drug development using in silico modeling

whitePaper | June 22, 2022

The technologic and pharmacologic advances that have enabled researchers to take aim at previously untreatable diseases have contributed to an increase in the number of molecules in the development pipeline that are challenging and difficult to manufacture.

Read More

Spotlight

National Institute of Molecular Genetics

The Istituto Nazionale di Genetica Molecolare (INGM) is a no-profit research foundation aimed at the discovery and initial development of new therapies and new diagnostics in the fields of tumors and autoimmune diseases. INGM comes to life to be a “translational” medical Research Institute that creates scientific knowledge capable of generating value on the basis of the intellectual property that ensues from its research activities. To achieve these objectives, INGM will develop scientific research strongly connected with clinics, drawing benefit from being located inside one of the most important European hospitals, the IRCCS Ospedale Maggiore of Milan. Research activities are coordinated by a Chief Scientific Officier with scientific and managerial expertise who is supported by a Scientific Advisory Board composed by researchers having a high international profile.

Events